Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 56-64

  Champoux, J J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

CANCER; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG DNA INTERACTION; DRUG EFFECT; HUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0034502496     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07025.x     Document Type: Conference Paper

References (47)

1. Mechanistic aspects of type-i topoisomerases
2. A model for the mechanism of human topoisomerase I
3. The effect of salt on the binding of the eucaryotic DNA nicking-closing enzyme to DNA and chromatin
4. Reconstitution of human topoisomerase I by fragment complementation
5. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases
6. Vaccinia DNA topoisomerase I: Single-turnover and steady-state kinetic analysis of the DNA strand cleavage and ligation reactions
7. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
8. The domain organization of human topoisomerase I
9. Domains of human topoisomerase I and associated functions
10. Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei
11. Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function
12. Expression of yeast DNA topoisomerase I can complement a conditional-lethal DNA topoisomerase I mutation in Escherichia coli
13. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I
14. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I
15. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
16. DNA topoisomerase-targeting antitumor drugs can be studied in yeast
17. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin
18. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin
19. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin
20. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
21. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I
22. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site
23. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex
24. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site
25. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay
26. The effects of camptothecin on the reaction and the specificity of the wheat germ type I topoisomerase
27. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I
28. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
29. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
30. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues
31. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells
32. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system
33. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites
34. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex
35. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin
36. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
37. Human DNA topoisomerase I: Quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage
38. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages
39. Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I
40. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures
41. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants
42. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin
43. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites
44. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line
45. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine
46. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis